Among the intermediate cytogenetic (IC-AML) patients, the presence of an ASXL1 mutation was associated with worse 2-year OS (14%) compared to patients without ASXL1 mutation (37%, p = 0.030, Figure 2A, Table 3). Here, ASXL1 is linked to acute myeloid leukemia.